[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy]

Gan To Kagaku Ryoho. 2017 Aug;44(8):703-705.
[Article in Japanese]

Abstract

We report a case of TNBC treated effectively with a platinum-based regimen after developing resistance to anthracycline and taxane-based neoadjuvant chemotherapy(NAC). A 59-year-old woman with a right breast mass and high fever visited our clinic and was diagnosed as having inflammatory triple negative breast cancer(iTNBC). She was treated with NAC of docetaxel, doxorubicin, and cyclophosphamide(TAC)using pegfilgrastim. After 5 courses of TAC, the therapy failed and the disease progressed. Thus, a combination regimen of gemcitabine and carboplatin(GC)was administered. The treatment was successful, and the patient underwent a curative operation after 6 courses of the GC therapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Docetaxel
  • Doxorubicin / administration & dosage
  • Drug Resistance, Neoplasm*
  • Female
  • Gemcitabine
  • Humans
  • Middle Aged
  • Taxoids / administration & dosage
  • Tomography, X-Ray Computed
  • Triple Negative Breast Neoplasms / diagnostic imaging
  • Triple Negative Breast Neoplasms / drug therapy*

Substances

  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Gemcitabine